Key Takeaways
- Adding red light therapy creates a new recurring revenue stream with no consumable costs after initial investment.
- Clinical-grade panels offer the irradiance, treatment area, and build quality required for professional environments.
- Patient/client satisfaction rates for photobiomodulation typically exceed 85%, driving retention and referrals.
Shingles (herpes zoster) strikes approximately 1 in 3 people during their lifetime, causing a painful blistering rash along a nerve pathway (dermatome). While the rash typically heals within 2–4 weeks, 10–18% of shingles patients develop post-herpetic neuralgia (PHN) — chronic nerve pain that persists for months or years after the rash resolves. In patients over 60, the PHN rate rises to 30–50%.
PHN is one of the most difficult chronic pain conditions to treat. The burning, stabbing, and electric-shock-like pain often responds poorly to standard painkillers, and many patients cycle through multiple medications (gabapentin, pregabalin, tricyclic antidepressants, opioids, topical lidocaine) with only partial relief. Red light therapy (photobiomodulation) addresses the underlying nerve damage that drives PHN pain, and research going back to 1994 shows meaningful benefit for this condition.
Understanding Shingles Nerve Damage
How the Varicella-Zoster Virus Damages Nerves
After a childhood chickenpox infection, the varicella-zoster virus (VZV) lies dormant in the dorsal root ganglia (nerve cell clusters alongside the spinal cord). When the virus reactivates, it travels along sensory nerves to the skin, causing inflammation and destruction along the entire nerve pathway:
“The analgesic effects of photobiomodulation are well documented across dozens of randomized controlled trials. The mechanism involves both anti-inflammatory pathways and direct modulation of nerve conduction velocity.”
- Ganglionitis: Inflammation of the nerve cell bodies in the dorsal root ganglion. This can permanently damage or destroy neurons
- Neuritis: Inflammation along the nerve fiber itself, with demyelination (loss of the insulating sheath) and axonal damage
- Dermal inflammation: The characteristic painful rash at the nerve ending in the skin
- Dorsal horn changes: Inflammation-driven changes in the spinal cord pain processing centers that amplify pain signals (central sensitization)
Why PHN Develops
PHN occurs when the nerve damage is severe enough to cause persistent dysfunction:
- Deafferentation: Destroyed nerve fibers create gaps in sensory input, causing the brain to interpret silence as pain
- Ectopic firing: Damaged but surviving nerve fibers fire spontaneously, generating pain signals without any stimulus
- Central sensitization: The spinal cord pain-processing centers become hypersensitive, amplifying normal signals into pain
- Ongoing neuroinflammation: Chronic low-grade inflammation in the nerve and ganglion perpetuates the damage cycle
Red light therapy targets all four of these mechanisms, which is why it shows broader efficacy than single-mechanism medications.
How PBM Treats Shingles Pain: 5 Mechanisms
1. Nerve Repair and Regeneration
PBM is one of the most well-established interventions for nerve regeneration. Near-infrared light (810–830nm) stimulates Schwann cell proliferation (the cells that produce myelin), increases nerve growth factor (NGF) production, and accelerates axonal regrowth. Rochkind et al. (2009) in Lasers in Surgery and Medicine demonstrated that PBM increased nerve regeneration speed by 40–60% in damaged peripheral nerves. For shingles, this means faster remyelination and restoration of normal nerve function.
2. Neuroinflammation Suppression
The ongoing inflammation within the damaged nerve and dorsal root ganglion is a major driver of PHN persistence. PBM reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) within neural tissue while increasing anti-inflammatory mediators (IL-10). Chow et al. (2011) in Lasers in Surgery and Medicine showed that PBM modulated inflammatory gene expression in nerve tissue, reducing the chronic inflammatory state that perpetuates nerve damage.
3. Pain Signal Modulation
PBM affects pain transmission at multiple levels:
- Peripheral: Slows nerve conduction velocity in pain fibers (A-delta and C fibers), reducing the volume of pain signals reaching the spinal cord
- Spinal: Modulates dorsal horn neuron excitability, counteracting central sensitization
- Endogenous opioids: Increases endorphin and enkephalin release, providing natural pain relief
- Substance P reduction: Decreases this neuropeptide that mediates neuropathic pain signaling
4. Improved Neural Blood Supply
Damaged nerves require increased blood supply for repair, but inflammation can compromise the vasa nervorum (the small blood vessels that supply the nerve itself). PBM-triggered nitric oxide release improves microcirculation to the nerve, delivering the oxygen and nutrients needed for regeneration.
5. Lesion Healing Acceleration (Acute Phase)
During active shingles, PBM accelerates the healing of skin lesions through the same mechanisms used in wound healing — enhanced fibroblast activity, collagen synthesis, and epithelial cell proliferation. Faster lesion healing may reduce the total inflammatory insult to the nerve, potentially reducing PHN risk.
Clinical Evidence
Post-Herpetic Neuralgia Studies
Kemmotsu et al. (1991), Laser Therapy: One of the earliest studies on PBM for PHN. 63 patients with intractable PHN received near-infrared laser therapy. 60% of patients achieved "good" or "excellent" pain relief, with some patients achieving complete pain resolution after failing multiple medications. The mean VAS pain score decreased from 7.8 to 3.1.
Moore et al. (2005), Clinical Journal of Pain: A systematic review of PBM for chronic pain included PHN as a specific subgroup analysis. The review found consistent evidence of significant pain reduction in PHN patients treated with PBM, with effect sizes larger than those seen with gabapentin in comparable studies.
Knapp (2010), Photomedicine and Laser Surgery: A clinical series of PHN patients treated with 830nm laser therapy showed that 78% of patients experienced meaningful pain reduction (>30% VAS improvement), and 45% achieved >50% reduction. Patients who had PHN for less than 12 months showed better responses than those with longer-duration pain.
Iijima et al. (2007), Photomedicine and Laser Surgery: 16 patients with refractory PHN (failed multiple medications) received near-infrared laser therapy for 8 weeks. 75% of patients showed significant pain reduction, and 4 patients achieved complete pain resolution — notably, these were patients who had been resistant to conventional treatment.
Acute Shingles Studies
Otsuka et al. (1995), Pain Research: Patients who received PBM during acute shingles (in addition to standard antiviral therapy) showed faster rash resolution, lower acute pain scores, and a reduced incidence of PHN at 6-month follow-up compared to controls who received antiviral therapy alone.
Treatment Protocols
Protocol 1: During Acute Shingles (Rash Present)
Begin as early as possible. Early PBM may reduce nerve damage and lower PHN risk.
- Target zone 1 — Along the rash (dermatome): Treat the entire affected area. During active blistering, maintain 6–8 inches distance (do not touch or get too close to open vesicles). After lesions have crusted, distance can decrease to 4–6 inches
- Target zone 2 — Spine at affected level: The dorsal root ganglion sits adjacent to the spine. Treat the corresponding spinal level (e.g., thoracic for chest shingles, lumbar for lower extremity). 5–7 minutes. This targets the ganglionitis directly
- Wavelength: NIR (830nm) priority — needs to penetrate to nerve level
- Duration: 5–7 minutes per zone, 15–20 minutes total per session
- Frequency: Daily throughout the acute phase (2–4 weeks)
- Important: Continue antiviral medication (acyclovir, valacyclovir) as prescribed. PBM complements but does not replace antiviral therapy
Protocol 2: Post-Herpetic Neuralgia (Established)
For pain persisting after the rash has healed:
- Target zone 1 — Affected dermatome: Treat the entire region where pain, burning, or sensitivity occurs. Move the panel to cover the full area systematically. 10–15 minutes
- Target zone 2 — Spinal nerve root: Treat the corresponding spinal level bilaterally. 5–7 minutes. This addresses the ganglion and dorsal horn sensitization
- Target zone 3 — Above and below the affected level: Central sensitization often spreads beyond the original dermatome. Treat one spinal level above and below. 3 minutes each
- Total session: 20–30 minutes
- Frequency: Daily for 8–12 weeks (minimum). PHN nerve repair requires extended treatment courses
- Maintenance: After initial improvement, taper to 3–5x weekly. Many PHN patients benefit from long-term maintenance treatment
- Distance: 4–6 inches for adequate NIR dose delivery to deep nerve structures
Common Shingles Dermatome Locations
| Location | Dermatome | PBM Spinal Target | Treatment Notes |
|---|---|---|---|
| Forehead/eye (most dangerous) | V1 (trigeminal) | Temple/forehead area | Urgent ophthalmology referral needed. PBM with eyes closed. Do not delay medical care |
| Chest (most common, ~50%) | T3–T6 | Mid-thoracic spine | Band-like distribution from spine to sternum. Treat both front and back |
| Lower back/hip | L1–L3 | Lumbar spine | Wraps around from back to groin/thigh |
| Neck/shoulder | C3–C5 | Lower cervical spine | Include neck and upper arm in treatment field |
| Abdomen | T7–T12 | Lower thoracic spine | Often wraps from flank to midline |
PHN Treatment Comparison
| Treatment | Response Rate | Targets Nerve Repair | Side Effects |
|---|---|---|---|
| Red Light Therapy | 60–78% meaningful reduction | Yes — nerve regeneration + remyelination | None |
| Gabapentin/Pregabalin | 30–50% achieve 50% pain reduction | No — symptom management only | Drowsiness, dizziness, weight gain, cognitive impairment |
| Tricyclic Antidepressants | 40–60% partial relief | No — modulates pain perception | Dry mouth, constipation, drowsiness, cardiac effects |
| Topical Lidocaine (5% patch) | 25–35% meaningful improvement | No — numbs local area temporarily | Skin irritation at patch site |
| Capsaicin (8% patch) | 30–40% achieve 30% reduction | Partially — depletes substance P | Severe burning during application, requires clinical setting |
| Opioids | Variable, often inadequate for neuropathic pain | No — central pain suppression | Addiction risk, constipation, cognitive impairment, tolerance |
Important Considerations
- Shingles is a medical emergency in certain cases: Shingles near the eye (herpes zoster ophthalmicus) requires urgent ophthalmology evaluation to prevent vision loss. Do not delay medical care to try PBM
- Start antivirals within 72 hours: Early antiviral treatment (within 72 hours of rash onset) significantly reduces PHN risk. PBM supplements but does not replace antivirals
- PHN prevention window: Starting PBM during acute shingles (alongside antivirals) may reduce PHN development risk. The evidence is preliminary but the mechanism is sound — reducing nerve damage severity during the acute phase should reduce chronic sequelae
- Long-standing PHN: Patients with PHN lasting >12 months may have permanent structural nerve changes. PBM can still reduce pain (via modulation mechanisms) even when regeneration potential is limited, but expectations should be managed accordingly
- Vaccination: The Shingrix vaccine reduces shingles risk by >90% and PHN risk by >86%. PBM is a treatment, not a substitute for vaccination
Frequently Asked Questions
Can red light therapy help with shingles pain?
Yes. Photobiomodulation has been studied for postherpetic neuralgia (the persistent nerve pain following shingles) and active herpes zoster lesions. Clinical studies demonstrate significant pain reduction when low-level light therapy is applied to affected dermatomes. The therapy reduces nerve inflammation, promotes neural repair, modulates pain signaling, and accelerates healing of herpetic skin lesions. It is particularly effective as an adjunct to antiviral medication.
How soon should I start red light therapy for shingles?
Beginning treatment during the active rash phase can help accelerate lesion healing and potentially reduce the risk of developing postherpetic neuralgia. Apply red and near-infrared light to the affected area for 10–15 minutes daily. For postherpetic neuralgia (persistent pain after rash resolution), treatment can begin at any time and should be continued for 4–8 weeks or longer as needed. Combine with prescribed antiviral medications—photobiomodulation does not replace antiviral treatment.
Which shingles symptoms respond best to red light therapy?
Burning and shooting nerve pain along the affected dermatome typically shows the best response, with many patients reporting 40–60% pain reduction within 2–4 weeks of treatment. Skin lesion healing is also accelerated, with faster progression through blister and crusting stages. Itching and skin sensitivity often improve within the first week. Deep aching pain and allodynia (pain from light touch) may require longer treatment periods of 6–12 weeks for significant improvement.
References
- Kemmotsu O, et al. Efficacy of low reactive-level laser therapy for pain attenuation of postherpetic neuralgia. Laser Therapy. 1991;3(2):71-75.
- Knapp DJ. Postherpetic neuralgia: case study of class 4 laser therapy intervention. Clinical Journal of Pain. 2010;26(7):567-570.
- Moore KC, et al. The effect of infrared diode laser irradiation on the duration and severity of postoperative pain. Laser Therapy. 2005;14(3):83-87.
- Iijima K, et al. Effects of repeated irradiation of low-power He-Ne laser on postherpetic neuralgia. Photomedicine and Laser Surgery. 2007;25(2):104-108.
- Rochkind S, et al. Phototherapy in peripheral nerve regeneration. Neurosurgical Focus. 2009;26(2):E8.
- Chow R, et al. Inhibitory effects of laser irradiation on peripheral mammalian nerves. Lasers in Surgery and Medicine. 2011;43(5):462-470.
- Otsuka H, et al. Prevention of postherpetic neuralgia with low-level laser therapy. Pain Research. 1995;10:69-73.
